You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.
It is possible that some of the products on the other site are not approved in the United Kingdom.
Targeted drug delivery (TDD) allows your cancer patients to take control of their pain by giving them the ability to manage breakthrough pain 3 times faster compared to
conventional medication and receive pain relief with less systemic opioid side effects.
Intrathecal baclofen (ITB) therapy can significantly improve spasticity, pain, and function in children with CP. ITB can also significantly improve both the child’s and parents’ quality of life, due to gains in the child’s independence and their ability to better manage daily activities.
Intrathecal baclofen (ITB) therapy significantly reduces disfunction due to spasticity, and significantly improves pain, function and qol, by improving your patient´s sleep, rest and life participation so they can enjoy activities they used to do.
Intrathecal baclofen (ITB) therapy significantly decreases the burden of spasticity in terms of muscle tone, tightness and spasms. ITB increases function and QOL, which might lead to improvements in sleep and rest, so that patients may regain their enjoyment of recreation and pastimes.
Intrathecal baclofen (ITB) therapy reduces post-stroke spasticity and pain, provides improvements in qol, functional ability, emotional behaviour and social interest, Thus allowing your patients to regain enjoyment in their daily activities.